Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice